How can Elicera’s iTANK technology boost CAR-T cell therapies?
Summary
Leveraging CAR-T therapies to fight solid tumors poses challenges since they have a highly immunosuppressive tumor microenvironment and a heterogenous target antigen expression. Elicera aims to resolve these challenges by arming CAR T-cells with its proprietary iTANK technology platform to directly counteract the immunosuppressive tumor microenvironment and elicit a second immune response by activating the patients’ own killer T-cells against the whole set of relevant target antigens on solid tumors.
Researcher Profile
